Trial Profile
Effects of azelnidipine on heart rate variability in patients with chronic kidney disease receiving angiotensin receptor blockers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Azelnidipine (Primary) ; Olmesartan medoxomil
- Indications Renal failure
- Focus Pharmacodynamics
- 02 Sep 2015 End date assumed from date of conference.
- 02 Sep 2015 New trial record